Alexion Pharmaceuticals Inc. (ALXN)'s Soliris® (eculizumab) Receives Positive Opinion From the Committee for Orphan Medicinal Products for Treatment of Neuromyelitis Optica (NMO)
7/16/2013 10:03:31 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Soliris® (eculizumab), the company’s first-in-class terminal complement inhibitor, has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) for the treatment of neuromyelitis optica (NMO), a life-threatening, ultra-rare neurological disorder. The positive opinion of the COMP has now been forwarded to the European Commission for final approval and publication in the community register. Soliris is not approved in any country for the treatment of patients with NMO.
Help employers find you! Check out all the jobs and post your resume.
comments powered by